Adaptimmune Therapeutics, which is developing cancer immunotherapies based on genetically engineered T-cell receptors, filed on Monday with the SEC to raise up to $150 million in an initial public offering.
The Abingdon, United Kingdom-based company, which was founded in 2008 , plans to list on the NASDAQ under the symbol ADAP. Adaptimmune Therapeutics initially filed confidentially on February 5, 2015. BofA Merrill Lynch, Cowen & Company and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
